Key facts
- Reborna Biosciences’s last known valuation is $15.2M (Jun 2025).
- It has raised $18.5M; the latest was Later Stage VC ($5.3M) in Jun 2025.
- Notable investors include Mitsubishi UFJ Capital, Nissay Capital, UntroD, Angel Bridge, Gogin Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Reborna Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Reborna Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Reborna Biosciences
Developer of a drug discovery technology designed to demonstrate fundamental treatment effects through the normalization of RNA function. The company's technology creates small-molecule drugs with an affinity for ribonucleic acid using the natural three-dimensional structure of RNA in vivo, enabling physicians to treat genetically rare diseases.
- Sector
- Healthcare
- HQ
- Fujisawa, Japan
- Founded
- 2018
- Employees
- 8
- Website
- rebornabiosciences.com/
- Ownership
- Privately Held (backing)
Reborna Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Reborna Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Reborna Biosciences in its N-PORT filings yet. We sweep new filings monthly.